Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

MorphoSys AG : quaterly earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2019 | 09:15am EDT

The company will report its earnings for Q1 2019 on 05/07/2019. Generally, the company reports earnings in line with the consensus. In recent months, the 10 analysts from Thomson Reuters consensus have revised their EPS estimates downward.


© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
10:58aMORPHOSYS : Presents Primary Analysis Data from L-MIND Study of Tafasitamab in c..
AQ
06/22MORPHOSYS : Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR..
EQ
06/14MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/14MORPHOSYS : Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (..
EQ
06/11MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/05MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
06/03MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/24MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/24MORPHOSYS : to Present at Upcoming Investor Conferences
AQ
05/23MORPHOSYS : to Present at Upcoming Investor Conferences
EQ
More news
Financials (€)
Sales 2019 74,8 M
EBIT 2019 -92,3 M
Net income 2019 -99,6 M
Finance 2019 381 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 31,8x
EV / Sales 2020 22,0x
Capitalization 2 762 M
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 90,7 €
Spread / Average Target 4,5%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Marc Cluzel Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Wendy S. Johnson Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-2.47%3 040
IQVIA HOLDINGS INC36.58%26 223
LONZA GROUP28.86%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION39.49%17 061
EXACT SCIENCES CORPORATION83.26%13 037